Hyloris Pharmaceuticals (XBRU:HYL) Days Sales Outstanding : 476.72 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Days Sales Outstanding?

Hyloris Pharmaceuticals's average Accounts Receivable for the six months ended in Dec. 2023 was €4.32 Mil. Hyloris Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was €1.65 Mil. Hence, Hyloris Pharmaceuticals's Days Sales Outstanding for the six months ended in Dec. 2023 was 476.72.

The historical rank and industry rank for Hyloris Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

XBRU:HYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 110.54 Med: 425.16 Max: 681.87
Current: 595.28

During the past 8 years, Hyloris Pharmaceuticals's highest Days Sales Outstanding was 681.87. The lowest was 110.54. And the median was 425.16.

XBRU:HYL's Days Sales Outstanding is ranked worse than
94.39% of 892 companies
in the Biotechnology industry
Industry Median: 72.19 vs XBRU:HYL: 595.28

Hyloris Pharmaceuticals's Days Sales Outstanding increased from Dec. 2022 (330.65) to Dec. 2023 (476.72).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Hyloris Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Hyloris Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Days Sales Outstanding Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

425.16

110.54

139.65

460.61

598.41

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial							125.80	366.06	330.65	760.52	476.72

Competitive Comparison of Hyloris Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Days Sales Outstanding falls into.

Hyloris Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Hyloris Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (5.127	+	4.1)	/	2 )	/	2.814	*	365
=	4.6135					/	2.814	*	365
=	598.41

Hyloris Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (4.541	+	4.1)	/	2 )	/	1.654	*	365 / 2
=	4.3205					/	1.654	*	365 / 2
=	476.72

Hyloris Pharmaceuticals (XBRU:HYL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Hyloris Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.